PortalPublikationenImmunohistochemically detected IDH1 mutation is rare and mos...

Immunohistochemically detected IDH1 mutation is rare and mostly heterogeneous in prostate cancer

Standard

Immunohistochemically detected IDH1 mutation is rare and mostly heterogeneous in prostate cancer. / Hinsch, Andrea; Brolund, Meta; Hube-Magg, Claudia; Kluth, Martina; Simon, Ronald; Möller-Koop, Christina; Sauter, Guido; Steurer, Stefan; Luebke, Andreas; Angerer, Alexander; Wittmer, Corinna; Neubauer, Emily; Göbel, Cosima; Büscheck, Franziska; Minner, Sarah; Wilczak, Waldemar; Schlomm, Thorsten; Jacobsen, Frank; Clauditz, Till Sebastian; Krech, Till; Tsourlakis, Maria Christina; Schroeder, Cornelia.

in: WORLD J UROL, Jahrgang 36, Nr. 6, 06.2018, S. 877-882.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Hinsch, A, Brolund, M, Hube-Magg, C, Kluth, M, Simon, R, Möller-Koop, C, Sauter, G, Steurer, S, Luebke, A, Angerer, A, Wittmer, C, Neubauer, E, Göbel, C, Büscheck, F, Minner, S, Wilczak, W, Schlomm, T, Jacobsen, F, Clauditz, TS, Krech, T, Tsourlakis, MC & Schroeder, C 2018, 'Immunohistochemically detected IDH1 mutation is rare and mostly heterogeneous in prostate cancer', WORLD J UROL, Jg. 36, Nr. 6, S. 877-882. https://doi.org/10.1007/s00345-018-2225-7

APA

Hinsch, A., Brolund, M., Hube-Magg, C., Kluth, M., Simon, R., Möller-Koop, C., Sauter, G., Steurer, S., Luebke, A., Angerer, A., Wittmer, C., Neubauer, E., Göbel, C., Büscheck, F., Minner, S., Wilczak, W., Schlomm, T., Jacobsen, F., Clauditz, T. S., ... Schroeder, C. (2018). Immunohistochemically detected IDH1 mutation is rare and mostly heterogeneous in prostate cancer. WORLD J UROL, 36(6), 877-882. https://doi.org/10.1007/s00345-018-2225-7

Vancouver

Hinsch A, Brolund M, Hube-Magg C, Kluth M, Simon R, Möller-Koop C et al. Immunohistochemically detected IDH1 mutation is rare and mostly heterogeneous in prostate cancer. WORLD J UROL. 2018 Jun;36(6):877-882. https://doi.org/10.1007/s00345-018-2225-7

Bibtex

@article{a1c408ddbea54f06a4dae1c0c1cb4143,
title = "Immunohistochemically detected IDH1 mutation is rare and mostly heterogeneous in prostate cancer",
abstract = "BACKGROUND: IDH1 mutations are oncogenic through induction of DNA damage and genome instability. They are of therapeutic interest because they confer increased sensitivity to radiation and cytotoxic therapy and hold potential for vaccination therapy.METHODS: In this study, we analyzed more than 17,000 primary prostate cancer tissues with a mutation-specific antibody for the IDH1R132H mutation.RESULTS: IDH1 mutation-specific staining was found in 42 of 15,531 (0.3%) interpretable cancers. IDH1 mutation was associated with higher preoperative PSA and Gleason grade (p < 0.05, each) but was unrelated to PSA recurrence. A comparison with other molecular tumor features available from earlier studies revealed that TMPRSS2-ERG fusion as well as deletion of PTEN, 5q21, 6q15, and 3p13 was less frequent in IDH1-mutated than in non-mutated cancer. Increased lethality of genetically instable, {"}aberration-rich{"} cancer cells in the presence of IDH1 mutations could possibly explain this observation. Heterogeneity analysis revealed a homogeneous mutation in only 1 of 16 IDH1-mutated cancers. This high degree of heterogeneity may profoundly limit therapeutic targeting of IDH1 mutations in prostate cancer.CONCLUSIONS: The data show that 0.3% of prostate cancers have an IDH1R132H mutation and that these are mostly heterogeneous. Once specific anti-IDH1 therapy becomes reality, only a very small group of prostate cancer patients may benefit from such a treatment.",
keywords = "Journal Article",
author = "Andrea Hinsch and Meta Brolund and Claudia Hube-Magg and Martina Kluth and Ronald Simon and Christina M{\"o}ller-Koop and Guido Sauter and Stefan Steurer and Andreas Luebke and Alexander Angerer and Corinna Wittmer and Emily Neubauer and Cosima G{\"o}bel and Franziska B{\"u}scheck and Sarah Minner and Waldemar Wilczak and Thorsten Schlomm and Frank Jacobsen and Clauditz, {Till Sebastian} and Till Krech and Tsourlakis, {Maria Christina} and Cornelia Schroeder",
year = "2018",
month = jun,
doi = "10.1007/s00345-018-2225-7",
language = "English",
volume = "36",
pages = "877--882",
journal = "WORLD J UROL",
issn = "0724-4983",
publisher = "Springer",
number = "6",

}

RIS

TY - JOUR

T1 - Immunohistochemically detected IDH1 mutation is rare and mostly heterogeneous in prostate cancer

AU - Hinsch, Andrea

AU - Brolund, Meta

AU - Hube-Magg, Claudia

AU - Kluth, Martina

AU - Simon, Ronald

AU - Möller-Koop, Christina

AU - Sauter, Guido

AU - Steurer, Stefan

AU - Luebke, Andreas

AU - Angerer, Alexander

AU - Wittmer, Corinna

AU - Neubauer, Emily

AU - Göbel, Cosima

AU - Büscheck, Franziska

AU - Minner, Sarah

AU - Wilczak, Waldemar

AU - Schlomm, Thorsten

AU - Jacobsen, Frank

AU - Clauditz, Till Sebastian

AU - Krech, Till

AU - Tsourlakis, Maria Christina

AU - Schroeder, Cornelia

PY - 2018/6

Y1 - 2018/6

N2 - BACKGROUND: IDH1 mutations are oncogenic through induction of DNA damage and genome instability. They are of therapeutic interest because they confer increased sensitivity to radiation and cytotoxic therapy and hold potential for vaccination therapy.METHODS: In this study, we analyzed more than 17,000 primary prostate cancer tissues with a mutation-specific antibody for the IDH1R132H mutation.RESULTS: IDH1 mutation-specific staining was found in 42 of 15,531 (0.3%) interpretable cancers. IDH1 mutation was associated with higher preoperative PSA and Gleason grade (p < 0.05, each) but was unrelated to PSA recurrence. A comparison with other molecular tumor features available from earlier studies revealed that TMPRSS2-ERG fusion as well as deletion of PTEN, 5q21, 6q15, and 3p13 was less frequent in IDH1-mutated than in non-mutated cancer. Increased lethality of genetically instable, "aberration-rich" cancer cells in the presence of IDH1 mutations could possibly explain this observation. Heterogeneity analysis revealed a homogeneous mutation in only 1 of 16 IDH1-mutated cancers. This high degree of heterogeneity may profoundly limit therapeutic targeting of IDH1 mutations in prostate cancer.CONCLUSIONS: The data show that 0.3% of prostate cancers have an IDH1R132H mutation and that these are mostly heterogeneous. Once specific anti-IDH1 therapy becomes reality, only a very small group of prostate cancer patients may benefit from such a treatment.

AB - BACKGROUND: IDH1 mutations are oncogenic through induction of DNA damage and genome instability. They are of therapeutic interest because they confer increased sensitivity to radiation and cytotoxic therapy and hold potential for vaccination therapy.METHODS: In this study, we analyzed more than 17,000 primary prostate cancer tissues with a mutation-specific antibody for the IDH1R132H mutation.RESULTS: IDH1 mutation-specific staining was found in 42 of 15,531 (0.3%) interpretable cancers. IDH1 mutation was associated with higher preoperative PSA and Gleason grade (p < 0.05, each) but was unrelated to PSA recurrence. A comparison with other molecular tumor features available from earlier studies revealed that TMPRSS2-ERG fusion as well as deletion of PTEN, 5q21, 6q15, and 3p13 was less frequent in IDH1-mutated than in non-mutated cancer. Increased lethality of genetically instable, "aberration-rich" cancer cells in the presence of IDH1 mutations could possibly explain this observation. Heterogeneity analysis revealed a homogeneous mutation in only 1 of 16 IDH1-mutated cancers. This high degree of heterogeneity may profoundly limit therapeutic targeting of IDH1 mutations in prostate cancer.CONCLUSIONS: The data show that 0.3% of prostate cancers have an IDH1R132H mutation and that these are mostly heterogeneous. Once specific anti-IDH1 therapy becomes reality, only a very small group of prostate cancer patients may benefit from such a treatment.

KW - Journal Article

U2 - 10.1007/s00345-018-2225-7

DO - 10.1007/s00345-018-2225-7

M3 - SCORING: Journal article

C2 - 29427004

VL - 36

SP - 877

EP - 882

JO - WORLD J UROL

JF - WORLD J UROL

SN - 0724-4983

IS - 6

ER -